PH26427A - Method of inhibiting interleukin-1-release - Google Patents

Method of inhibiting interleukin-1-release Download PDF

Info

Publication number: PH26427A
Authority: PH; Philippines
Prior art keywords: animal; release; compound; alleviate; suffering
Prior art date: 1987-03-17

Application number

PH36645A

Other languages

English (en)

Inventor

George Ku

Niall Doherty

Original Assignee

Merrell Dow Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-03-17

Filing date

1988-03-16

Publication date

1992-07-15

1988-02-18 Priority claimed from US07/151,521 external-priority patent/US4870101A/en

1988-03-16 Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma

1992-07-15 Publication of PH26427A publication Critical patent/PH26427A/en

Links

238000000034 method Methods 0.000 title claims description 12
230000002401 inhibitory effect Effects 0.000 title claims 2
108010002352 Interleukin-1 Proteins 0.000 title description 2
102000000589 Interleukin-1 Human genes 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 17
241001465754 Metazoa Species 0.000 claims description 12
206010061218 Inflammation Diseases 0.000 claims description 6
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 6
230000004054 inflammatory process Effects 0.000 claims description 6
108010063738 Interleukins Proteins 0.000 claims description 3
102000015696 Interleukins Human genes 0.000 claims description 3
229960002563 disulfiram Drugs 0.000 claims description 3
206010012601 diabetes mellitus Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims 1
230000000694 effects Effects 0.000 description 11
230000001404 mediated effect Effects 0.000 description 8
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
210000004027 cell Anatomy 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
241000252067 Megalops atlanticus Species 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
241000699670 Mus sp. Species 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
206010048998 Acute phase reaction Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001214257 Mene Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
241000246358 Thymus Species 0.000 description 1
235000007303 Thymus vulgaris Nutrition 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
BGYHLZZASRKEJE-UHFFFAOYSA-N [3-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxy]-2,2-bis[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyloxymethyl]propyl] 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CCC(=O)OCC(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)(COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)COC(=O)CCC=2C=C(C(O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 BGYHLZZASRKEJE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000036523 atherogenesis Effects 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000003413 degradative effect Effects 0.000 description 1
125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
-1 dimethylethyl Chemical group 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000007775 late Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
241000894007 species Species 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000001585 thymus vulgaris Substances 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PH36645A 1987-03-17 1988-03-16 Method of inhibiting interleukin-1-release PH26427A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2658787A	1987-03-17	1987-03-17
US07/151,521 US4870101A (en)	1987-03-17	1988-02-18	Method of inhibiting interleukin-1 release

Publications (1)

Publication Number	Publication Date
PH26427A true PH26427A (en)	1992-07-15

Family

ID=26701422

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH36645A PH26427A (en)	1987-03-17	1988-03-16	Method of inhibiting interleukin-1-release

Country Status (5)

Country	Link
EP (1)	EP0284879A3 (de)
JP (1)	JP2650039B2 (de)
AU (1)	AU601554B2 (de)
DK (1)	DK143688A (de)
PH (1)	PH26427A (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807884A (en) *	1992-10-30	1998-09-15	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5380747A (en) *	1992-10-30	1995-01-10	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5821260A (en) *	1992-10-30	1998-10-13	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5792787A (en) *	1995-06-07	1998-08-11	Emory University	Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
IL122891A0 (en)	1998-01-11	1998-08-16	Yeda Res & Dev	Pharmaceutical compositions comprising a thiocarbamate
IL122892A0 (en) *	1998-01-11	1998-08-16	Yeda Res & Dev	Pharmaceutical compositions comprising a thiocarbamate
US7816403B2 (en)	1998-09-08	2010-10-19	University Of Utah Research Foundation	Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
GB0020351D0 (en)	2000-08-17	2000-10-04	Catalyst Biomedica Ltd	Treatment of hyperproliferative diseases
WO2004064856A2 (en) *	2003-01-23	2004-08-05	Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung	Proteins involved in the regulation of energy homeostasis
US10369108B2 (en)	2013-03-15	2019-08-06	Mylan Laboratories, Inc.	Hot melt granulation formulations of poorly water-soluble active agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1782111A (en) *	1925-08-04	1930-11-18	Naugatuck Chem Co	Method of manufacturing tetra-alkylated thiuramdisulphides

1988
- 1988-03-15 EP EP19880104085 patent/EP0284879A3/de not_active Withdrawn
- 1988-03-16 AU AU13161/88A patent/AU601554B2/en not_active Ceased
- 1988-03-16 PH PH36645A patent/PH26427A/en unknown
- 1988-03-16 DK DK143688A patent/DK143688A/da not_active Application Discontinuation
- 1988-03-17 JP JP63062073A patent/JP2650039B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0284879A2 (de)	1988-10-05
AU601554B2 (en)	1990-09-13
EP0284879A3 (de)	1990-10-17
JPS63258410A (ja)	1988-10-25
AU1316188A (en)	1988-09-15
DK143688A (da)	1988-09-18
JP2650039B2 (ja)	1997-09-03
DK143688D0 (da)	1988-03-16

Publication	Publication Date	Title
US4870101A (en)	1989-09-26	Method of inhibiting interleukin-1 release
US4975467A (en)	1990-12-04	Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions
Vadas et al.	1983	Activation of antibody-dependent cell-mediated cytotoxicity of human neutrophils and eosinophils by separate colony-stimulating factors.
US4997850A (en)	1991-03-05	Treating agent for osteroarthritis
PH26427A (en)	1992-07-15	Method of inhibiting interleukin-1-release
US5002879A (en)	1991-03-26	Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
EP0276803B1 (de)	1991-10-16	1-(4-Hydroxy-3,5-di-tert.-butyl-benzoyl)-homopiperazin, verschiedene von dessen Derivaten, Verfahren zur Herstellung dieser Verbindungen, die sie enthaltenden Arzneimittel und ihre Verwendung
EP0774255A1 (de)	1997-05-21	Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
KR960005704B1 (ko)	1996-05-01	인터루킨-1의 방출을 억제하고 인터루킨-1이 매개된 질환을 완화시키기 위한 약제학적 조성물
JPH0667832B2 (ja)	1994-08-31	腫瘍性疾患の治療に用いるプログルミド含有医薬組成物
DE3786456T2 (de)	1994-02-03	Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen.
CN1150758A (zh)	1997-05-28	制备棘酸的方法和含有棘酸的药物组合物
US7906150B2 (en)	2011-03-15	Preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium
DE3779562T2 (de)	1993-01-21	Golgi-alpha-mannosidase ii-inhibitoren enthaltende zubereitungen.
US5011857A (en)	1991-04-30	Method of inhibiting interleukin-1 release
US5034412A (en)	1991-07-23	Method of inhibiting interleukin-1 release
JPS62263127A (ja)	1987-11-16	自己由来のｌａｋ細胞、インタ−ロイキン−２、及びオルニチンデカルボキシラ−ゼ阻害剤による腫瘍の処置
JP3515140B2 (ja)	2004-04-05	ブロイラー用腹水症防止剤及び腹水症防止方法
EP0120019B1 (de)	1986-12-17	Pharmazeutische zubereitungen mit zytostatischer wirkung
JPH045005B2 (de)	1992-01-30
DE3650311T2 (de)	1995-10-12	Verwendung von Quinazolinen zur Herstellung eines Arzneimittels zur Behandlung und Vorbeugung von Arrhythmie.
JP2001524526A (ja)	2001-12-04	サイトカインの細胞生産を阻害するための方法
CN110025606B (zh)	2022-01-18	吉非罗齐的新用途
Porter et al.	1971	4, 4, 6-Trimethyl-3, 4-dihydropyrimidine-2-thiol, an effective inhibitor of dopamine-β-hydroxylation in vivo
EP1037617A1 (de)	2000-09-27	Substituierte amidino verbindungen zur behandlung von chronischen obstruktiven lungenkrankheiten